Atea Pharmaceuticals, Inc.

Stage 2 · Advancing · week 10

As of Oct 22, 2026, Atea Pharmaceuticals is in Stage 2, the uptrend phase, now in week 10 (since Aug 13, 2026). It closed at $4.05, 34.1% below its 52-week high and below its 200-day average, which is rising.

$4.05

-0.74% today

$325M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is AVIR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 20w

S3 15w

S4 36w

S2 21w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 20w → S1 6w → S2 10w → S3 15w → S4 4w → S1 2w → S2 1w → S1 2w → S4 36w → S1 4w → S2 9w → S3 6w → S4 6w → S1 2w → S2 21w → S3 11w → S2 10w current

Total tracked: 166 weeks across 17 stage runs.

AVIR among Biotechnology129th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…129	AVIRAtea Pharmaceuticals, Inc.	Stage 2 · wk 10	72	−23.3%

vs 52W High

-34.1%

$2.96 lo$6.15 hi

34.1% below 52W high, far from high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 10

1w13w26w

Week 10, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-17.5%

200 DMA: $4.91 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

1.13x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-23.3%

-14.4%

-26.6%

YTD

+16.4%

+23.1%

Scan Membership

Breakout Watch

Latest: 2024-09-19

3 appearances in last 60 days. First seen: 2022-08-08.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 10 · Vol 1.13x

2026-10-21S2

Wk 10 · Vol 1.30x

2026-10-20S2

Wk 10 · Vol 1.05x

2026-10-19S2

Wk 10 · Vol 1.43x

2026-10-16S2

Wk 10 · Vol 1.28x

2026-10-15S2

Wk 9 · Vol 1.19x

2026-10-14S2

Wk 9 · Vol 1.54x

2026-10-13S2

Wk 9 · Vol 1.13x

2026-10-12S2

Wk 9 · Vol 0.70x

2026-10-09S2

Wk 9 · Vol 0.56x

2026-10-08S2

Wk 8 · Vol 1.21x

2026-10-07S2

Wk 8 · Vol 0.85x

Moving averages & range

50 DMA

$5.18

200 DMA

$4.91

52W High

$6.15

52W Low

$2.96

5D Low

$4.05

Resistance levels (recent highs)

20d High

$5.21

60d High

$5.83

120d High

$5.83

250d High

$6.15

Next resistance

+28.6%

to 20d High

ROE

-58.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.6

Atea Pharmaceuticals: quick answers

What stage is Atea Pharmaceuticals in?

As of Oct 22, 2026, Atea Pharmaceuticals (AVIR) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 13, 2026 and is in week 10. What the four stages mean

Is Atea Pharmaceuticals in an uptrend?

Yes. Atea Pharmaceuticals is in a Stage 2 uptrend. It trades 17.5% below its 200-day average, which is rising.

How far is Atea Pharmaceuticals from its 52-week high?

Atea Pharmaceuticals closed at $4.05 on Oct 22, 2026, 34.1% below its 52-week high of $6.15. Its 52-week low is $2.96.

How has Atea Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Atea Pharmaceuticals is up 23.1% over the past year and up 16.4% so far in 2026.

Which sector and industry is Atea Pharmaceuticals in?

Atea Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.